Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Cancer Prev Res (Phila). 2011 Jun;4(6):793–802. doi: 10.1158/1940-6207.CAPR-11-0057

Table 2.

Iloprost treatment effects on bronchial histology

IloProst
Placebo
Treatment Effect1
Baseline 6-Month Change Baseline 6-Month Change Difference 95% CI P-Value
All Completers2
All Biopsies
 Average 2.64 2.41 −0.23 2.56 2.54 −0.02 −0.15 (−0.39, 0.09) 0.210
 Worst 4.25 3.85 −0.40 3.91 4.14 0.23 −0.43 (−0.84, −0.03) 0.038
 Dysp. Index 34.97 27.27 −7.70 34.23 33.32 −0.92 −5.97 (−13.28, 1.33) 0.112
Former Smokers3
All Biopsies
 Average 2.12 1.73 −0.39 2.07 2.11 0.04 −0.41 (−0.71, −0.11) 0.010
 Worst 3.59 2.83 −0.76 3.11 3.68 0.57 −1.10 (−1.76, −0.45) 0.002
 Dysp. Index 20.81 10.90 −9.91 22.90 24.60 1.70 −12.45 (−20.98, −3.92) 0.006
Current Smokers4
All Biopsies
 Average 3.13 3.05 −0.07 2.93 2.87 −0.06 0.06 (−0.30, 0.42) 0.743
 Worst 4.87 4.81 −0.06 4.51 4.49 −0.03 0.12 (−0.36, 0.60) 0.621
 Dysp. Index 48.22 42.58 −5.64 42.81 39.91 −2.90 −0.33 (−11.70, 11.05) 0.955
1

Adjusted for baseline level of the outcome variable plus smoking status.

2

N = 60 (iloprost), N = 65 (placebo).

3

N = 29 (iloprost), N = 28 (placebo).

4

N = 31 (iloprost), N = 37 (placebo).